Our article was published in Nature Brand magazine (Biopharma Dealmakers)!
It's about the concept of metabolic-associated fatty liver disease (MAFLD) and how we work with it, which could have important implications for drug development in non-alcoholic fatty liver disease (NAFLD).
As we know, the lack of appropriate mouse models of the disease for NAFLD is a barrier to drug development and is thought to be one of the reasons why the development of drugs for NAFLD has not yet been successful. In recent years, there has also been a call for the diagnosis and classification of the disease from NAFLD to MAFLD, and we believe that this change in disease criteria will have important implications for the development of therapeutics for MAFLD.
We take pride in being the pioneers of the world's first preclinical model with a type 2 diabetic background that emulates the progression from steatosis to non-alcoholic steatohepatitis (NASH), fibrosis, and finally hepatocellular carcinoma (HCC). As we navigate this transition, SMC is keen on developing additional animal models that reflect MAFLD and its subtypes, filling the gap in the understanding and treatment of the disease.
▶ Read more article！[ From NAFLD to MAFLD: navigating the future of fatty liver treatment ]
If you are interested in this article or our STAM™ mice or services, please feel free to contact us.